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Purpose: To compare the effects of benzalkonium chloride (BAC)-preserved and unpreserved antiallergic eye drops on
the human 3D-reconstituted corneal epithelial model (3D-HCE).
Methods: 3D-HCE were treated for 24 h followed or not by a 24 h post-incubation recovery period (24 h+24 h) with
phosphate-buffered saline (PBS), 0.01% BAC, unpreserved formulations of ketotifen, N Acetyl-Aspartyl Glutamic Acid
(NAAGA),  cromoglycate,  or  BAC-preserved  commercial  formulations  of  ketotifen,  olopatadine,  epinastine,  and
levocabastine. The 3D-HCE viability was evaluated using the 3-(4,5-Dimethylthiazol-2-yl) -2,5-Diphenyltetrazolium
Bromide (MTT) test at 24 h and 24 h+24 h. At 24 h, the numbers of Cluster of Differentiation 54 (CD54)- and Ki67-
immunopositive cells as well as the number of apoptotic deoxynucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL)-positive cells were evaluated on 3D-HCE frozen sections. The expression of the tight junction-associated
protein occludin was also assessed using fluorescence confocal microscopy on flat-mounted 3D-HCE epithelia.
Results: The MTT and the TUNEL tests revealed a significant decrease of cell viability and an increased apoptosis in the
superficial layers of the 3D-HCE only when treated with BAC-containing formulations and in a BAC concentration-
dependent manner. The expression of CD54 and Ki67 in the basal layers was also increased in this group. A concentration-
dependent disorganization of occludin distribution in the epithelium treated with BAC-containing solutions was also
observed. The unpreserved formulations induced effects comparable to the control.
Conclusions: BAC-preserved solutions decreased cell viability and induced apoptosis in a concentration-dependent
manner. Moreover, they induced CD54 expression, proliferation in the basal layers, and changes in the distribution of
occludin, which is consistent with a disorganization of the tight-junctions and suggests the loss of the epithelial barrier
function. On the contrary, the unpreserved solutions did not impair cell structures and viability, suggesting a better
tolerance for the ocular surface. As allergic patients often exhibit impaired and inflammatory ocular surface, BAC-free
compounds should be the first choice when treating allergic conjunctivitis.
To limit and counteract the clinical manifestations of
allergic diseases, antiallergic compounds can be used. One of
these molecules, ketotifen fumarate, has demonstrated both
H1-receptor antagonism and mast cell stabilizing properties
while inhibiting chemotaxis and eosinophil activation [1,2].
Moreover, ketotifen fumarate was shown to be well tolerated
and effective in reducing the signs and symptoms of allergic
conjunctivitis  [3-6].  Allergic  conjunctivitis,  however,  has
often a tendency to become chronic, due to repeated allergic
challenge  or  progressive  impairment  of  the  tear  film  and
ocular surface [7,8].
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As preservatives are usually used to prevent multidose
eyedrop  microbial  contamination,  their  chronic
administration may cause further ocular surface changes, at
the  levels  of  tear  film  and  conjunctiva.  They  can  induce
cytotoxic effects and deleterious reactions when used over
long-term  periods.  Indeed,  the  mostly  used  preservative
benzalkonium chloride (BAC) was already shown to exhibit
toxic and inflammatory effects in clinical, in vivo and in vitro
studies [9-20]. Chronic use of BAC in eye drops is known to
be  responsible  for  apoptosis  and  oxidative  stress  on
conjunctival cells, and to induce conjunctival inflammation
that has demonstrated potentially harmful effects on glaucoma
outcome, e.g., on glaucoma surgery efficacy [17,21-25].
In this context, the implementation of very sensitive tools
to predict eye tolerance is critical for ophthalmologists, who
may be faced with long-term induced toxicity of substances
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745used  at  low  concentration  in  ophthalmic  preparations.
Supplied  by  SkinEthic®  Laboratories  (Nice,  France),  the
reconstructed  three-dimensional  (3D)  model  of  human
corneal  cells  (3D-HCE)  is  an  appropriate  model  for  pre-
screening  or  investigating  the  undesirable  effects  of
ophthalmic drugs. It constitutes an interesting alternative to
animal testing that is time-consuming and often invasive and
may  lack  suited  sensitive  tools  able  to  detect  subclinical
reactions [26-28]. Multi-endpoint analyses using adapted and
improved techniques on such 3D-models have already proved
efficacy for the assessment of BAC toxicity [28] and eyedrop
tolerance [27].
The objective of this study was to investigate a large range
of commonly used antiallergic eye drops in this 3D-HCE
system and compare the tissue changes after treatment with
BAC-preserved  commercial  formulations  of  ketotifen,
olopatadine,  epinastine  or  levocabastine,  and  unpreserved
commercial  formulations  of  ketotifen,  N  Acetyl-Aspartyl
Glutamic Acid (NAAGA), or cromoglycate. Particularly, our
purpose  was  to  determine  the  involvement  of  BAC  in
epithelial cell damage induced after treatment with BAC-
preserved and unpreserved antiallergic eyedrops.
METHODS
Tissue model and antiallergic solution treatments: The 3D-
HCE model (SkinEthic® Laboratories, Nice, France) consists
of immortalized HCE cells grown vertically on a 0.5 cm2 insert
permeable  polycarbonate  filter.  All  the  experiments  were
conducted as published previously [27-29]. Thirty microliters
of each solution were applied on the apical surface of 3D-
HCEs for 24 h and 24 h followed by 24 h additional recovery
time: sterile phosphate-buffered saline (PBS) used as negative
control solution, BAC solutions at 0.01% used as positive
control, the commercial solutions of 0.01% BAC-containing
ketotifen fumarate 0.025% (Zaditen®; Novartis Pharma SAS,
Rueil-Malmaison,  France),  0.01%  BAC-containing
olopatadine chlorhydrate 0.1% (Opatanol®; Patanol®; Alcon,
Ft.  Worth,  TX),  0.01%  BAC-containing  epinastine
chlorhydrate 0.05% (Purivist®; Allergan, Irvine, CA), 0.015%
BAC-containing  levocabastine  chlorhydrate  0.05%
(Levophta®; Chauvin Bausch & Lomb, Montpellier, France),
preservative-free ketotifen fumarate 0.025% (Zalerg®; Thea,
Clermont-Ferrand, France), preservative-free NAAGA 4.9%
(NAABAK®;  Thea)  and  preservative-free  sodium
cromoglycate 2% (Cromabak®; Thea; Table 1).
The recovery period (24 h) was chosen to assess the
potential reversibility of toxic effects on 3D-HCE. Six series
of 3D-HCE were used for each solution: two series for cell
viability  3-(4,5-Dimethylthiazol-2-yl)  -2,5-
Diphenyltetrazolium Bromide (MTT) testing, two series for
histomorphologic  analyses  after  hematoxylin  and  eosin
staining and immunohistological analyses on cryosections,
and two series for immunofluorescent labeling on the most
superficial  layers  of  3D-HCE  by  en-face  confocal
microscopic analyses.
Modified MTT test: The modified MTT test was used to assess
cellular  viability  as  described  previously  [27-29].
Experiments were conducted in duplicate. The 3D-HCEs were
transferred in 24-well plates containing 300 μl of the MTT
solution diluted at 0.5 mg/ml in culture medium and 300 µl of
the same MTT solution were applied on the apical surface of
the 3D-HCEs. Reconstituted tissues were incubated for 3 h.
Then,  the  3D-HCEs  were  transferred  into  24-well  plates
containing 750 µl isopropanol, and 750 µl isopropanol were
added to the apical surface of the 3D-HCEs. After a 2-h
agitation,  solutions  were  vigorously  homogenized  before
reading the absorbance at 570 nm versus 690 nm. Results were
expressed as a percentage of cell viability compared to the
negative control, PBS. Analyses were performed using Safire
technology (Tecan, Lyon, France).
Confocal immunofluorescence analyses on cryosections and
entire  epithelia:  After  incubation  with  the  9  different
solutions, the 3D-HCE samples were transferred into Petri
dishes containing PBS to be separated into two pieces using
a  surgical  scalpel.  Each    e c e i p    f o     tissue  was    embedded    in
OCT® medium (Tissue-Tek, Miles Inc., Elkhart, IN), and
frozen at –80 °C. Vertical cryosections (10 μm thick) were
then  cut  using  a  cryotome  (Leica  CM  3050s,  Leica
Microsystems AG, Wetzlar,  Germany).  The  cryosections
were   fixed   in   4%  paraformaldehyde  (PFA)  for  20  min 
before  immunofluorescent  labeling  of   the  tight   junction
protein occludin.
Detection of apoptosis (TUNEL assay), inflammation (CD54)
and proliferation (Ki67) on 3D-HCE cryosections:
Apoptosis,  TUNEL  assay—Apoptosis  in  the  tissue
layers  was  detected  using  a  terminal  deoxynucleotidyl
TABLE 1. BENZALKONIUM CHLORIDE (BAC) AND ACTIVE COMPOUND CONTENT OF THE ANTIALLERGIC EYE DROPS TESTED.
Eye drops Active compound content BAC content
Ketotifen fumarate (Zaditen®; Novartis Pharma SAS,Rueil-Malmaison, France) 0.025% 0.01%
Olopatadine chlorhydrate (Opatanol®; Patanol®; Alcon, Ft. Worth, TX) 0.1% 0.01%
Epinastine chlorhydrate (Purivist®; Allergan, Irvin, CA) 0.05% 0.01%
Levocabastine chlorhydrate (Levophta®; Chauvin Bausch & Lomb, Montpellier, France) 0.05% 0.015%
Preservative-free ketotifen fumarate (Zalerg®; Thea, Clermont-Ferrand, France) 0.025% -
Preservative-free NAAGA (NAABAK®; Thea, Clermont-Ferrand, France) 4.9% -
Preservative-free sodium cromoglycate (Cromabak®; Thea, Clermont-Ferrand, France) 2% -
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746transferase-mediated dUTP-nick end labeling (TUNEL) kit
containing  TUNEL  enzyme  and  TUNEL  label  (Roche
Diagnostics, Meylan, France). Nuclei were stained with 4',6-
diamidino-2-phenylindole (DAPI) and the cryosections were
mounted  in  an  anti-fade  medium  (Vectashield;  Vector
Laboratories, Burlingame, CA).
CD54  (ICAM-1)  and  Ki67  immunostaining—First,
samples were fixed with 4% PFA for 10 min. Then, samples
were permeabilized with 0.01%-diluted Triton X100® (Sigma
Chemical Company, St. Louis, MO) for 5 min. Cells were
incubated in presence of the mouse anti-human cluster of
differentiation 54 (CD54) (IgG1; 1:100 final dilution; BD
Biosciences, PharMingen, San Diego, CA), the mouse anti-
human Ki67 (1:25 final dilution; Immunotech, Marseilles,
France)  or  with  the  isotypic  control  mouse  IgG1  (BD
Biosciences) primary antibodies. Alexa 488 conjugated-goat
anti-mouse IgG (Invitrogen-Molecular Probes, Eugene, OR)
was used as second antibody at a 1:500 dilution. Nuclei were
labeled with propidium iodide (PI) and cryosections were
mounted in Vectashield. Samples were analyzed under a laser
confocal microscope equipped with a digital camera (E800;
PCM  2000;  Nikon,  Champigny-sur-Marne,  France).
Immunopositive  cells  were  then  counted  under  the  20×
objective of the microscope in three different areas. Results
were calculated as the average of counts, and finally expressed
as cell numbers per mm of epithelial length (mm.E.L.) after
each treatment.
Confocal immunofluorescence on entire epithelia for
tight  junction  staining—The  rabbit  anti-human  occludin
(IgG1; 1:100 dilution; Dako, Glostrup, Denmark) was used
for tight junction staining. Alexa 488-conjugated goat anti-
rabbit  was  used  as  second  antibody.  Samples  were  then
analyzed  under  a  laser  confocal  microscope  (E800;  PCM
2000; Nikon) for detecting occludin expression.
Quantification  and  statistical  analysis:  Quantification  of
TUNEL-, ICAM-1-, and Ki67-positive cells was performed
manually, using a microscopic grid on images under 400×
magnification. Results were expressed as mean cell numbers
per  millimeter  of  epithelial  length  (mm.E.L).  Standard
deviations  were  indicated.  Statistical  comparisons  were
performed using two-way analysis of variance (ANOVA),
followed by multiple pairwise comparisons using the Fisher’s
adjustment (Statview V for Windows; SAS Institute, Cary,
NC).
RESULTS
Cell viability: MTT test: The PBS negative control did not
affect the cell viability neither at 24 h nor after the 24 h-
recovery  period  (24  h+24  h;  Figure  1).  The  unpreserved
formulation of ketotifen fumarate KETO-BAC(-) showed the
same level of cell viability as PBS at 24 h (99,4%) and a slight
decrease of viability after 24 h+24 h (86.9% of the control).
The  preservative-free  formulations  of  NAAGA  and
cromoglycate, NAA-BAC(-) and CRO-BAC(-), also showed
a weak decrease of cellular viability at 24 h (93.2% and 95.1%,
respectively) and after 24 h+24 h (87.7% for both; Figure 1).
Conversely, as expected according to previous studies
[28],  0.01%  BAC  showed  a  significant  decrease  of  cell
viability at 24 h and after 24 h+24 h (59.6% and 55% viability,
respectively).  Cell  viability  decreased  in  a  BAC-
concentration  dependant  manner  for  the  BAC-containing
antiallergic formulations, with a highest toxicity observed
with the 0.015% BAC-containing levocabastine chlorhydrate
0.05% [LEVO-BAC(+)]. Cell viability levels were 66.8% at
24 h and 55.3% at 24 h+24 h for 0.01% BAC-containing
ketotifen fumarate 0.025% [KETO-BAC(+)], 63.7% at 24 h
and  60.5%  at  24  h+24  h  for  0.01%  BAC-containing
olopatadine chlorhydrate 0.1% [OPA-BAC(+)], 52.1% at 24
h  and  56.6%  at  24  h+24  h  for  0.01%  BAC-containing
epinastine chlorhydrate 0.05% [EPI-BAC(+)], and 46.3% at
24 h and 44.3% at 24 h+24 h for LEVO-BAC(+).
Immunofluorescence analyses and quantification of apoptosis
(TUNEL):  Few  apoptotic  cells  were  observed  after  PBS
incubation (6.4 cells/mm.E.L.). Similar levels of apoptosis
were  observed  with  the  3  unpreserved  antiallergic
formulations (Figure 2): 9.2 cells/mm.E.L. for NAA-BAC(-),
12.2 cells/mm.E.L. for CRO-BAC(-), and 8.6 cells/mm.E.L.
for  KETO-BAC(-),  without  any  statistically  significant
difference compared to PBS.
Consistent with previously published reports with the
same technique [28,29], BAC at 0.01% significantly increased
the  number  of  TUNEL-positive  cells  compared  to  PBS
(p<0.0014). Apoptosis also increased on cells treated with all
BAC-containing antiallergic formulations, with a statistically
significant difference compared to PBS (p<0.0014): 28, 29.3,
46.6,  and  75.5  cells/mm.E.L.  for  KETO-BAC(+),  OPA-
BAC(+), EPI-BAC(+), and LEVO-BAC(+), respectively.
Immunofluorescence  analyses  and  quantification  of  the
inflammation marker ICAM-1 (CD54): CD54 expression was
measured  at  70  cells/mm.E.L.  on  PBS-treated  3D-HCE
cultures  (Figure  3).  The  three  unpreserved  antiallergic
formulations  NAA-BAC(-),  CRO-BAC(-),  and  KETO-
BAC(-) expressed CD54 at low levels too, respectively, 60.3,
59.3, and 64 cells/mm.E.L., with no statistically significant
differences compared to PBS. Conversely, 0.01% BAC and
LEVO-BAC(+) showed increased levels of CD54 expression
with a statistically significant difference compared to PBS
(p<0.001): 150.4 cells/mm.E.L. for 0.01% BAC and 142 cells/
mm.E.L. for LEVO-BAC(+). KETO-BAC(+), OPA-BAC(+),
EPI-BAC(+) showed increased levels of CD54 expression
too,  but  no  statistically  significant  difference  was  found
neither with PBS nor with 0.01% BAC i.e., 98.5, 114 and 92
cells/mm.E.L. for KETO-BAC(+), OPA-BAC(+) and EPI-
BAC(+), respectively.
Immunofluorescence  analyses  of  cell  proliferation  marker
Ki67: After PBS treatment (Figure 4), few proliferating cells
were observed (29.2 cells/mm.E.L), scattered throughout the
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747entire epithelium. Similar findings were observed with the
unpreserved  antiallergic  treatments,  with  no  statistically
significant differences compared to PBS: 28.3, 30.0, and 27.3
cells/mm.E.L. for NAA-BAC(-), CRO-BAC(-), and KETO-
BAC(-),  respectively  (Figure  4).  Conversely,  numerous
proliferating cells, with a greater number located in the basal
layer, were found after 0.01% BAC, KETO-BAC(+), OPA-
BAC(+),  and  EPI-BAC(+)  with  a  statistically  significant
difference (p<0.04) compared to PBS: 55.3, 45, 45, and 55
cells/mm.E.L.,  respectively.  With  LEVO-BAC(+),  no
proliferative cells were observed, most likely due to the deep
impairment of corneal cells as this group showed the most
important number of apoptotic cells.
En-face confocal microscopic analysis of the tight junction-
associated protein occludin: En-face confocal microscopic
analysis of 3D-HCE cultures treated with PBS, NAA-BAC(-),
CRO-BAC(-), and KETO-BAC(-) revealed a fine membrane
immunostaining of occludin in large superficial cells, forming
a  ring  around  the  cells  (Figure  5).  This  kind  of  occludin
expression  clearly  disappeared  after  treatment  with  either
0.01% BAC, KETO-BAC(+), OPA-BAC(+), EPI-BAC(+), or
LEVO-BAC(+), all showing damaged cells with non-specific
staining.
DISCUSSION
In this study, the toxicological model of 3D-reconstructed
cornea was very helpful to demonstrate the effects of BAC-
preserved  solutions  on  corneal  cells  in  vitro,  showing
increased apoptosis, CD54 expression, proliferation in the
basal  layers  and  changes  in  the  distribution  of  occludin
induced with BAC-containing antiallergic treatments. On the
contrary,  the  unpreserved  ketotifen,  NAAGA  and
cromoglycate  solutions  did  not  impair  cell  structures  and
viability, suggesting a better tolerance for the ocular surface.
The  highly  differentiated,  three-dimensional  epithelial
system of human ocular origin is a desirable model for pre-
screening or investigating the effects of ophthalmic drugs. It
frees  the  experimenter  from  interspecies  differences  and
allows a better approach to the ocular epithelial physiology
than  monolayer  models  and  cells  originating  from  other
organs. It also constitutes an interesting alternative to animal
testing,  respecting  the  ethical  guidelines  of  animal
experimentation, especially the 3R rule (refining, reducing
and replacing the use of animals) [30,31]. The reconstructed
three dimensional (3D) model of human corneal cells (3D-
HCE), supplied by SkinEthic® Laboratories, was found to
resemble  the  corneal  epithelium  of  the  human  eye  in
morphology and thickness [32]. Such a 3D-system models is
not only useful to demonstrate the different effects of toxic
substances  on  specific  cell  types,  but  also  shows  the
interactions between the cells and the spatial effects induced
by the toxic. Moreover, epithelium cultures at the air-liquid
interface are easy-to-handle and facilitate in vivo-like product
Figure  1.  Cell  viability  MTT  test.
Cellular viability of 3D-HCEs treated
with PBS, 0.01% BAC, NAA-BAC(-),
CRO-BAC(-), KETO-BAC(-), KETO-
BAC(+),  OPA-BAC(+),  EPI-BAC(+),
or LEVO-BAC(+) for 24 h followed or
not by a 24 h post-incubation period (24
h+24  h-recovery).  BAC  induced  a
concentration-dependent  decrease  of
cellular  viability.  At  24  h,  the
unpreserved  NAA-BAC(-),  CRO-
BAC(-),  and  KETO-BAC(-)
formulations  induced  a  slight  or
insignificant  decrease  of  cellular
viability,  while  the  KETO-BAC
(+), OPA-BAC(+), EPI-BAC(+), and
LEVO-BAC(+)  BAC-containing
formulations induced a marked decrease
of cellular viability compared to control.
After  the  24-h  recovery  period,  the
unpreserved  formulations  showed  a
weak  additional  decrease  of  cellular
viability,  while  the  BAC-containing
formulations  still  induced  a  strong
decrease of cellular viability compared
to control, showing irreversible damage
to  3D-HCE.  Results  are  expressed  as
percentage of cell viability compared to
the PBS control.
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748exposures. The 3D-HCEs were found to express cytokeratin-3
and  include  hemidesmosomes  within  the  basal  layers.
Furthermore, they can inhibit the flow of ionic material such
as Na-fluorescein across their surface [32,33], suggesting the
presence of a functional epithelial barrier. Different types of
intercellular  junctions  have  been  identified  in  the  corneal
epithelium  ex  vivo.  Among  them,  adherens  junctions,
comprising  the  E-cadherin  protein,  serve  to  anchor  cells
together [34]. Also, the tight-junctions, originally defined as
zonula occludentes (ZO) and comprising occludin, ZO-1 and
other proteins, are thought to provide the hydrophobic barrier
preventing the free passage of molecules between adjacent
Figure 2. Apoptosis analysis (TUNEL).
Localization of TUNEL positive cells
(green) on 3D-HCE samples after 24 h
of incubation with PBS (A), 0.01% BAC
(B),  KETO-BAC(-)  (C),  KETO-
BAC(+) (D), NAA-BAC(-) (E), OPA-
BAC(+)  (F),  CRO-BAC(-)  (G),  EPI-
BAC(+)  (H),  LEVO-BAC(+)  (I).
Nuclei were stained with DAPI (blue).
No  or  very  rare  apoptotic  cells  were
observed after PBS (A), KETO-BAC(-)
(C),  KETO-BAC(+)  (D)  and  NAA-
BAC(-) (E) treatments. KETO-BAC(+)
(D)  and  OPA-BAC(+)  (F)  induced
moderate expression of apoptosis, and
0.01% BAC (B), EPI-BAC(+) (H) and
LEVO-BAC(+)  (I)  induced  a  greater
number  of  TUNEL-positive  cells
principally in the apical cell layers, and
also in the middle epithelial layers with
EPI-BAC(+)  (H)  and  LEVO-BAC(+)
(I).  Deeper  modifications  were
observed with 0.015% BAC-containing
LEVO-BAC(+) (I) compared to 0.01%
BAC  (B),  with  a  greater  number  of
TUNEL-positive  cells  in  the  middle
epithelial layers and a higher level of
vacuolization  in  the  basal  epithelial
layers  observed  with  LEVO-BAC(+)
(I). The quantification of apoptotic cells
with the TUNEL assay (J) showed that
apoptotic  cell  number  increased  in  a
BAC concentration-dependent manner.
BAC  at  0.01%  and  the  four  BAC-
containing  formulations  KETO-
BAC(+),  OPA-BAC(+),  EPI-BAC(+)
and  LEVO-BAC(+)  showed  much
higher expression of apoptotic TUNEL-
positive cells than did the unpreserved
formulations  NAA-BAC(-),  CRO-
BAC(-), KETO-BAC(-) at 24 h. Results
are expressed as cell number per mm of
epithelial length (mm.E.L.): Mean±SD
*Statistically  significant  compared  to
PBS  with  p<0.0014.  **Statistically
significant  compared  to  0.01%  BAC
with p<0.0014. †Statistically significant
compared  to  EPI-BAC(+)  with
p<0.0014.  $Statistically  significant
compared  to  LEVO-BAC(+)  with
p<0.0014.
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749epithelial cells [35-37]. In a previous study [28], we developed
a  new  procedure  of  the  classical  MTT  test  used  on  3D-
reconstituted epidermal and corneal models to evaluate the
viability. This procedure showed increased sensitivity levels
and  allowed  detecting  slight  damage  even  in  the  most
superficial layers. Therefore, it is well suited to the prediction
of low to very low irritant potential, especially when products
are used repeatedly during long-term periods of time, like in
allergic conjunctivitis, when repeated allergenic challenge or
ocular  surface  impairment  occur  and  require  sustained
therapy.
Although the morphological relevance and sensitivity of
the  3D-HCE  model  allowed  the  modeling  of  cumulative
effects that may approach conditions obtained after long-term
application of eye-drops [27], our in vitro findings cannot
fully be extrapolated to in vivo conditions. Indeed, preserved
eye  drops  may  be  less  toxic  in  vivo,  according  to  the
continuous action of the eyelids, the permanent renewal of
ocular surface epithelia, and the presence of the preocular
mucin layer and glycocalyx. Conversely, the accumulation of
BAC-containing eye drops in the eye and the long-term use
of eye drops in allergic patients with ocular surface disorders
will  emphasize  the  risk  of  toxic  reactions  and  further
contribute to inflammatory stimulation throughout the ocular
surface, at least at a subclinical level [38].
In the present study, using our modified MTT procedure,
we evaluated the effects of either preserved or unpreserved
antiallergic formulations on cellular viability and correlated
Figure  3.  Inflammation  analysis.
Immunolocalization  of  CD54
(ICAM-1) positive cells (green) on 3D-
HCE samples after 24 h of incubation
with PBS (A), 0.01% BAC (B), KETO-
BAC(-) (C), KETO-BAC(+) (D), NAA-
BAC(-) (E), OPA-BAC(+) (F), CRO-
BAC(-) (G), EPI-BAC(+) (H), LEVO-
BAC(+) (I). Nuclei were stained with
propidium  iodide  (PI,  red).  PBS  (A),
KETO-BAC(-) (C), NAA-BAC(-) (E)
and CRO-BAC(-) (G) showed a weak
expression  of  CD54.  A  significant
increase  of  CD54  expression  was
observed  after  the  treatments  with
0.01%  BAC  (B)  and  LEVO-BAC(+)
(I), showing a green staining in all the
epithelial  layers.  LEVO-BAC(+)  (I)
showed  deeper  modifications  with  a
higher loss of continuity between cells
and  a  higher  level  of  vacuolization
observed in the basal epithelial layers.
KETO-BAC(+) (D), OPA-BAC(+) (F)
and  EPI-BAC(+)  (H)  showed  an
intermediate CD54 expression that was
localized  in  all  epithelial  layers.
Quantification  of  CD54-positive  cells
(J) showed a higher CD54 expression
with BAC at 0.01% or the four BAC-
containing  formulations  KETO-
BAC(+),  OPA-BAC(+),  EPI-BAC(+)
and  LEVO-BAC(+)  than  with  the
unpreserved  formulations  NAA-
BAC(-), CRO-BAC(-), KETO-BAC(-)
at  24  h.  *Statistically  significant
compared  to  PBS  with  p<0.001.
**Statistically significant compared to
0.01% BAC with p<0.001. Results are
expressed  as  cell  number  per  mm  of
epithelial length (mm.E.L.): Mean±SD.
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750these results with those of a TUNEL assay performed on 3D-
HCE frozen sections. Then, we investigated on entire 3D-
HCE and using en-face confocal microscopy the changes of
expression  and  spatial  distribution  of  cellular  markers
involved in intercellular junctions such as occludin after the
different antiallergic treatments.
Thus, with this procedure, we were able to demonstrate
concentration-dependent cytotoxic effects of BAC at 24 h, the
absence of significant cellular viability decrease following
treatment  with  the  ketotifen,  NAAGA  and  cromoglycate
BAC-free formulations, and a cell viability decrease similar
to that disclosed by the 0.01% BAC treatment with the BAC-
containing antiallergic formulations of ketotifen, olopatadine,
epinastine and levocabastatine. We confirmed the toxic and
proinflammatory  effects  of  the  BAC-containing  solutions
using a TUNEL assay and CD54 immunostaining performed
on  3D-HCE  frozen  sections  and  found  a  significantly
increased number of apoptotic cells and an increased CD54
Figure  4.  Proliferation  analysis.
Immunolocalization  of  Ki67  positive
cells (green) on 3D-HCE samples after
24h of incubation with PBS (A), 0.01%
BAC (B), KETO-BAC(-) (C), KETO-
BAC(+) (D), NAA-BAC(-) (E), OPA-
BAC(+)  (F),  CRO-BAC(-)  (G),  EPI-
BAC(+)  (H),  LEVO-BAC(+)  (I).
Nuclei  were  stained  with  propidium
iodide  (PI,  red).  PBS  (A),  KETO-
BAC(-)  (C),  NAA-BAC(-)  (E)  and
CRO-BAC(-)  (G)  showed  a  weak
expression  of  Ki67  in  all  epithelial
layers.  BAC  at  0.01%  (B),  KETO-
BAC(+)  (D),  OPA-BAC(+)  (F),  and
EPI-BAC(+) (H) showed a higher Ki67
expression in all epithelial layers too.
With LEVO-BAC(+), no Ki67 positive
cells were observed, most likely due to
the  deep  impairment  of  corneal  cells
with  a  most  likely  inhibition  of
proliferative  capabilities  of  3D-HCE
submitted at this higher concentration in
BAC.  Quantification  of  Ki67-positive
cells  was  concordant  with  these
observations  (J).  *Statistically
significant  compared  to  PBS  with
p<0.04.  **Statistically  significant
compared to 0.01% BAC with p<0.001.
$Statistically  significant  compared  to
the other solutions tested. Results are
expressed  as  cell  number  per  mm  of
epithelial length (mm.E.L.): Mean±SD.
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751expression  following  exposure  to  0.01%  BAC  and  BAC-
containing  solutions  compared  to  the  control.  Finally,  we
examined the integrity of the structural and functional barrier
conferred by the tight-junctions by assessing the distribution
pattern of the occludin protein. The tight-junctions regulate
the passive movement of fluids, electrolytes, macromolecules
and  cells  through  the  paracellular  pathway,  thereby
contributing  to  the  corneal  defense  system  and  to  the
maintenance of the corneal homeostasis. In the mouse cornea,
the occludin distribution pattern was already described as
altered  by  a  detergent  treatment  (Triton  X100)  using
immunohistochemistry [39]. In a previous study, Chuan et al.
[40] showed the effects of contact lens multipurpose solutions
on  the  corneal  cells’  barrier  function  using  fluorescein
permeability assay and immunofluorescent staining for tight
junctions proteins (ZO-1 and occludin). Recently, we also
demonstrated that occludin mRNA expression was correlated
to BAC early toxic effects [28]. Our results were consistent
with those studies, showing the disturbance of occludin tight-
junction  protein  distribution  after  BAC-containing
antiallergic treatments.
Currently, allergic conjunctivitis incidence is increasing
in developed countries. According to Manners T et al. [41],
15% of eye related consultations in general practice are due
to allergic conjunctivitis. Recommended topical treatments
for symptoms of allergic conjunctivitis include topical mast
cell  stabilizers  and/or  topical  antihistamines  (H1-receptor
antagonists).  Some  of  the  new  antiallergic  drugs  now
available may have both effects and sometimes additional
properties, such as the ability to inhibit the expression of cell
adhesion molecules (CAMs) on the cell surface or to attenuate
inflammatory mediator release [1,3-6,42-45].
Figure 5. Tight junction-associated protein occludin. Immunofluorescence analysis of occludin expressions using en-face confocal microscopy
after treatment with PBS (A), 0.01% BAC (B), NAA-BAC(-) (C) CRO-BAC(-) (D), KETO-BAC(-) (E), KETO-BAC(+) (F), OPA-BAC(+)
(G), EPI-BAC(+) (H), LEVO-BAC(+) (I). Bar=100 µm.
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752The panel of eye drops tested in the present study was
deemed  to  be  fairly  representative  of  the  predominantly
prescribed therapeutic antiallergic molecules at the time of
these experiments in France. Indeed, among the commercial
antiallergic eye drops, one can distinguish between two types
of  formulations,  according  to  the  presence  of  BAC  as
preservative.  Currently,  the  antihistamines  olopatadine,
epinastine and levocabastine are available only as preserved
solutions  whereas  ketotifen  is  recently  accessible  in  both
formulations. These four antihistamines constitute a group of
comparable products from the therapeutic use viewpoint and
all of them are available as preserved solutions. We deemed
it interesting to add the preservative-free ketotifen solution in
the comparison. Naaga and cromoglycate eye drops belong to
a different class of antiallergic agents, i.e., the mast cells
degranulation inhibitors. Although they were both available
as preserved and unpreserved formulations, we chose to only
test their unpreserved formulations in order not to weigh the
experiment down all the more since the preserved eye drop
forms of these two molecules are now much less used in
therapeutics than their unpreserved counterparts. Overall, our
panel choice was conducted by the actuality of the antiallergic
armamentarium that is available to the patients.
There is currently enough evidence from clinical, in vivo,
and in vitro studies that long-term use of preserved topical
drugs  may  induce  several  deleterious  effects  on  ocular
surface, being responsible for ocular discomfort, tear film
instability,  conjunctival  inflammation,  subconjunctival
fibrosis  and  epithelial  apoptosis  [9].  Several  studies  have
confirmed the participation of high concentrations of BAC-
preserved  eye  drops  in  induction  of  ocular  surface
inflammation, allergy, fibrosis, punctate corneal staining, and
dry eye syndrome [9,38,46,47]. Three mechanisms have been
described: detergent effects inducing loss of tear film stability;
immunoallergic reactions; and direct toxic effects to epithelial
cells [48,49]. Other experimental and clinical studies have
shown that the long-term use of BAC-containing ophthalmic
solutions  can  induce  conjunctival  stroma  infiltrates  and
overexpression  of  inflammation-  or  apoptosis-related
molecules, such as class II antigen HLADR, ICAM-1, Fas
antigen, or the apoptotic marker Apo 2.7 [50-52].
In the present study, we showed that BAC-containing eye
antiallergic  solutions  may  decrease  cell  viability,  induce
apoptosis, ICAM-1 expression and proliferation in the basal
layers,  and  changes  in  the  distribution  of  occludin.
Conversely,  the  unpreserved  ketotifen,  NAAGA  and
cromoglycate formulations did not impair cell structures and
viability, suggesting a better tolerance for the ocular surface.
These findings were consistent with several previous in vitro
or  ex  vivo  studies  that  demonstrated  BAC  toxicity  and
potential  advantages  of  BAC-free  formulations  [9].
Moreover, the present results support our earlier findings on
antiallergic preserved and unpreserved eye-drops. Indeed, in
a  previous  study,  we  showed  that  antiallergic  eye  drops
preserved with BAC induced high ICAM-1 expression levels,
apoptosis and oxidative stress and reduced cellular viability
in opposition to the unpreserved formulations of NAAGA and
cromoglycate [53].
In addition, our results were consistent with a recent study
by Ayaki et al. [54] on corneal and conjunctival cell lines that
showed  that  cell  toxicity  was  mostly  affected  by  the
concentration of BAC rather than the active component of
antiallergic ophthalmic solutions. The use of a large range of
commonly antiallergic eye drops in the present study was
useful  to  support  this  point,  showing  BAC-concentration
dependent  toxic  effects  in  all  experiments.  This  may
emphasize the fact that epithelial toxicity was most likely
induced  by  the  preservative  (BAC)  than  by  the  active
antiallergic compound in the present study too.
These findings strongly support the use of preservative-
free  solutions  in  patients  with  chronic  eye  diseases  and
treatments  over  the  long-term,  especially  in  allergic
conjunctivitis or dry eye conditions. Definitely, preservative-
free antiallergic medications may decrease the adverse effects
of chronic topical medications, which could lead to better
tolerability, lower treatment discontinuations and improved
quality of life of patients with ocular allergic diseases.
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